Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sonia Caprio

Pediatric Endocrinology New Haven, CT Medical Doctor

NPI 1972586196 CMS profile 225513

800 Howard Ave, New Haven, CT 06519

Open in the dashboard

General payments

$188,493

72 records reported · program years 2019–2025

Research payments

$17,468

Paid to them · 10 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$107,176 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Sonia Caprio of New Haven, CT is reported in the CMS Open Payments database as having received $188,493 across 72 general payments and $17,468 in research payments paid to them. Separately, studies naming them as principal investigator received $107,176 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $35,625 4
2024 General $71,026 15
2024 Research $1,250 1
2023 General $15,272 5
2022 General $7,760 5
2022 Research $1,250 1
2021 General $15,988 8
2021 Research $2,950 2
2020 General $24,131 8
2020 Research $8,402 5
2019 General $18,693 27
2019 Research $3,616 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sonia Caprio
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Sonia Caprio were reported at $35,625. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Sonia Caprio Pediatric Endocrinology median Middle half National median
2019 $18,693 $196 $68–$845 $163
2020 $24,131 $124 $37–$722 $114
2021 $15,988 $134 $35–$691 $132
2022 $7,760 $177 $47–$726 $149
2023 $15,272 $236 $75–$887 $160
2024 $71,026 $259 $91–$979 $164
2025 $35,625 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eli Lilly and Company $127,518 19 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $15,501 14 payments
  3. AstraZeneca UK Limited $12,600 5 payments
  4. Novo Nordisk Inc $8,971 5 payments
  5. Boehringer Ingelheim International GmbH $8,576 7 payments
  6. Daiichi Sankyo Inc. $7,984 12 payments
  7. Sanofi-Aventis U.S. LLC $6,669 6 payments
  8. Genzyme Corporation $500 1 payment
  9. Abbott Laboratories $109 1 payment
  10. Corcept Therapeutics $50 1 payment
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $182,687 37 payments
  2. Travel and Lodging $4,082 13 payments
  3. Food and Beverage $1,225 21 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $500 1 payment
Products named General payments · program years 2019–2025
  1. TRULICITY $22,200 5 payments
  2. JARDIANCE $15,454 13 payments
  3. Welchol $7,984 12 payments
  4. ONGLYZA $7,200 3 payments
  5. FARXIGA $5,400 2 payments
  6. PRALUENT Cardiology/Vascular Diseases $3,711 4 payments
  7. PRALUENT Cardiovascular $3,458 3 payments
  8. FreeStyle Libre 3 $109 1 payment
  9. Korlym $50 1 payment
  10. Victoza $39 1 payment
  11. Other $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $8,550 3 payments
  2. AstraZeneca UK Limited $3,616 1 payment
  3. Regeneron Pharmaceuticals, Inc. $2,552 3 payments
  4. Sanofi-Aventis U.S. LLC $2,500 2 payments
  5. Genzyme Corporation $250 1 payment

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record